Sort   by:  
 Page size 
UnknownDurable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Not available
S-EPMC5590803 | biostudies-literature
UnknownComorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.
Not available
S-EPMC4178523 | biostudies-literature
UnknownPhase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
Not available
S-EPMC3732010 | biostudies-literature
UnknownContinued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.
Not available
S-EPMC6553811 | biostudies-literature
UnknownGraft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
Not available
S-EPMC3625710 | biostudies-literature
UnknownEffects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Not available
S-EPMC11873788 | biostudies-literature
UnknownHigher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607 | biostudies-literature
Sort   by:  
 Page size